Yes indeed they have continued their good run with numbers.
But, the key monitorable was Vaccine and biosimilar opportunities.
Good to see; finally they are about to start manufacturing. (With delay of few months for sure)
As per the commentary, they have received NOC for the facilities and final license is process formality.
Which definitely opening new doors of opportunity.
Negative is, they are still continuing their look for acquisition opportunity in bio-CDMO. Which they are doing from last 3 quarters. Nothing concrete happening.
China opportunity is also being dragged in similar lines, may be china approvals will also take long times, like in india. Or they may not do it! geo politics? 